| 1 |
Rajkumar SV. Multiple myeloma: 2023 update on diagnosis, risk-stratification, and management [J]. Am J Hematol, 2023, 98(1): 120-148.
|
| 2 |
Malard F, Neri P, Bahlis NJ, et al. Multiple myeloma [J]. Nat Rev Dis Primers, 2024, 10(1): 45.
|
| 3 |
Kumar SK, Dispenzieri A, Lacy MQ, et al. Refractory multiple myeloma: definitions, mechanisms, and management [J]. Lancet Oncol, 2014, 15(7): e288-e298.
|
| 4 |
Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world [J]. Trends Cell Biol, 2012, 22(8): 407-417.
|
| 5 |
Schneider JL, Cuervo AM. Autophagy and human disease: emerging themes [J]. Curr Opin Genet Dev, 2014, 26: 16-23.
|
| 6 |
Nikesitch N, Rebeiro P, Ho LL, et al. The role of chaperone-mediated autophagy in Bortezomib resistant multiple myeloma [J]. Cells, 2021, 10(12): 3464.
|
| 7 |
Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy [J]. J Biol Chem, 2007, 282(33): 24131-24145.
|
| 8 |
Li Y, Li S, Wu H. Ubiquitination-proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress [J]. Cells, 2022, 11(5): 851.
|
| 9 |
Lamy L, Ngo VN, Emre NC, et al. Control of autophagic cell death by caspase-10 in multiple myeloma [J]. Cancer Cell, 2013, 23(4): 435-449.
|
| 10 |
Milani M, Rzymski T, Mellor HR, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib [J]. Cancer Res, 2009, 69(10): 4415-4423.
|
| 11 |
Tang P, Yu Z, Sun H, et al. CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy [J]. EBioMedicine, 2024, 100: 104961.
|
| 12 |
Chen J, Cao W, Huang X, et al. TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy [J]. Blood Adv, 2023, 7(19): 5752-5770.
|
| 13 |
Zang X, Wang J, Xia Y, et al. LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma [J]. Leuk Res, 2022, 123: 106967．
|
| 14 |
Wu HQ, Qin RC, Li WJ, et al. Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway [J]. Acta Pharmacol Sin, 2025, 46(7): 2041-2055.
|
| 15 |
Xia J, He Y, Meng B, et al. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma [J]. Mol Oncol, 2020, 14(4): 763-778.
|
| 16 |
Riz I, Hawley TS, Hawley RG. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models [J]. Oncotarget, 2015, 6(17): 14814-14831.
|
| 17 |
Neumeister P, Schulz E, Pansy K, et al. Targeting the microenvironment for treating multiple myeloma [J]. Int J Mol Sci, 2022, 23(14): 7627.
|
| 18 |
Filippi I, Saltarella I, Aldinucci C, et al. Different adaptive responses to hypoxia in normal and multiple myeloma endothelial cells [J]. Cell Physiol Biochem, 2018, 46(1): 203-212.
|
| 19 |
Wang Y, Xu W, Yan Z, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways [J]. J Exp Clin Cancer Res, 2018, 37(1): 63.
|
| 20 |
Bar-Natan M, Stroopinsky D, Luptakova K, et al. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1 [J]. Br J Haematol, 2017, 176(6): 929-938.
|
| 21 |
Yan Y, Chen X, Wang X, et al. The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer [J]. J Exp Clin Cancer Res, 2019, 38(1): 171.
|
| 22 |
De Veirman K, Rao L, De Bruyne E, et al. Cancer associated fibroblasts and tumor growth: focus on multiple myeloma [J]. Cancers (Basel), 2014, 6(3): 1363-1381.
|
| 23 |
Zhang X, Zhang H, Lan H, et al. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies [J]. Front Immunol, 2023, 14: 1101495.
|
| 24 |
Sun J, Corradini S, Azab F, et al. IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma [J]. Leukemia, 2024, 38(11): 2355-2365.
|
| 25 |
Sun J, Park C, Guenthner N, et al. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy [J]. J Immunother Cancer, 2022, 10(4): e003975.
|
| 26 |
Zhu Y, Jian X, Chen S, et al. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma [J]. Cell Metab, 2024, 36(1): 159-175.e8.
|
| 27 |
Gao X, Feng Q, Zhang Q, et al. Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis [J]. J Biomed Sci, 2025, 32(1): 9.
|
| 28 |
Gu Z, Xia J, Xu H, et al. NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase [J]. J Hematol Oncol, 2017, 10(1): 17.
|
| 29 |
Zhou W, Yang Y, Xia J, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers [J]. Cancer Cell, 2013, 23(1): 48-62.
|
| 30 |
Tibullo D, Giallongo C, Romano A, et al. Mitochondrial functions, energy metabolism and protein glycosylation are interconnected processes mediating resistance to bortezomib in multiple myeloma cells [J]. Biomolecules, 2020, 10(5): 696.
|
| 31 |
Waldschmidt JM, Kloeber JA, Anand P, et al. Single-cell profiling reveals metabolic reprogramming as a resistance mechanism in BRAF-mutated multiple myeloma [J]. Clin Cancer Res, 2021, 27(23): 6432-6444.
|
| 32 |
Vogl DT, Stadtmauer EA, Tan KS, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma [J]. Autophagy, 2014, 10(8): 1380-1390.
|
| 33 |
Ma R, Yu D, Peng Y, et al. Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells [J]. Acta Biochim Biophys Sin (Shanghai), 2021, 53(6): 775-783.
|
| 34 |
Ghazi PC, O'Toole KT, Srinivas Boggaram S, et al. Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer [J]. Elife, 2024, 13: RP96992.
|
| 35 |
Chen Y, Xie X, Wang C, et al. Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities [J]. Cell Death Dis, 2020, 11(8): 712.
|
| 36 |
Ray A, Du T, Wan X, et al. A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death [J]. Blood Cancer J, 2024, 14(1): 58.
|
| 37 |
Tang L, Zhang H, Zhou F, et al. Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies [J]. Cancer Commun (Lond), 2024, 44(3): 408-432.
|
| 38 |
Zhong Y, Tian F, Ma H, et al. FTY720 induces ferroptosis and autophagy via PP2A/AMPK pathway in multiple myeloma cells [J]. Life Sci, 2020, 260: 118077.
|